Divis Laboratories Financial Statements

Divis Laboratories (DIVISLAB) reported revenue of ₹97.12B in FY2025 with net income of ₹21.91B. Total assets stood at ₹169.32B and free cash flow was ₹2.15B.

Divis Laboratories Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		70.32B	90.74B	81.12B	81.84B	97.12B
Cost of Rev. Cost of Revenue		-23.24B	-29.67B	-30.54B	-31.29B	-37.25B
Gross Profit		47.08B	61.07B	50.58B	50.55B	59.87B
SGA Sales, General & Admin		-17.85B	-21.11B	-23.46B	-25.11B	-26.67B
Op. Income Operating Income		26.67B	36.84B	23.69B	21.66B	29.18B
PBT Profit Before Tax		26.66B	36.84B	23.69B	21.63B	29.16B
Net Income		19.84B	29.60B	18.23B	16.00B	21.91B
Dil. Shares Diluted Shares		265.51M	265.47M	265.47M	265.47M	265.48M
Diluted EPS		74.73	111.52	68.69	60.27	82.53

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Divis Laboratories's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Divis Laboratories Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		61.75B	83.52B	93.12B	96.75B	100.81B
Non-curr. assets Total non-current assets		45.99B	50.23B	51.27B	57.95B	68.51B
Total assets		107.74B	133.75B	144.39B	154.70B	169.32B
Curr. liabilities Total current liabilities		11.12B	11.96B	11.01B	12.78B	14.52B
Non-curr. liab. Total non-current liabilities		3.67B	4.51B	5.71B	6.21B	5.11B
Total liabilities		14.79B	16.47B	16.72B	18.99B	19.63B
Total equity		92.95B	117.28B	127.67B	135.71B	149.69B
Total liab. & eq. Total liabilities & equity		107.74B	133.75B	144.39B	154.70B	169.32B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Divis Laboratories's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Divis Laboratories Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		26.66B	36.84B	23.69B	21.63B	29.16B
Operating CF Cash flow Operating Activities		19.47B	19.12B	24.60B	12.61B	16.53B
Capex Investments in PPE		-9.10B	-7.13B	-4.73B	-10.03B	-14.38B
Investing CF Cash flow Investing Activities		751.30M	-21.95B	-27.08B	-2.69B	-8.04B
Dividend Paid		0	-5.31B	-7.96B	-7.96B	-7.96B
Financing CF Cash flow Financing Activities		-348.90M	-5.32B	-7.97B	-7.99B	-7.99B
Cash (start) Cash at beginning of period		431.50M	20.30B	12.15B	1.70B	3.63B
Cash (end) Cash at end of period		20.30B	12.15B	1.70B	3.63B	4.13B
FCF Free Cash Flow		10.37B	11.99B	19.87B	2.58B	2.15B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Divis Laboratories's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025